Pharming Earns $15M up Front as Part of Deal with Santarus for HAE Drug
Approval of Rhucin/Ruconest in Europe is imminent, firm claims, with BLA filing planned by year-end. Santarus is to pay Pharming $15 million up front as part of an agreement for development and commercializati…
Read guide →